HRTX HERON THERAPEUTICS, INC. /DE/
Pharmaceutical Preparations · Nasdaq · SEC CIK 818033 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-4.4%
TTM net income YoY-58.8%
TTM EPS YoY-22.2%
Revenue 3-yr CAGR6.5%
Net income 3-yr CAGR—
Margins
Gross margin71.5%
Operating margin-5.7%
Net margin-14.5%
FCF margin-9.7%
EBITDA margin-4.4%
Returns
ROE-217.8%
ROA-9.0%
ROIC (approx.)—
Asset turnover0.62x
Leverage & solvency
Liabilities / assets97.9%
Debt / equity0.00x
Current ratio2.33x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.64x
Accruals ratio-3.3%
Payout ratio—
Capex / revenue0.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $35.25M | $37.67M | $34.71M | $40.59M | $38.21M | $37.20M | $38.90M | $40.78M |
| Cost of revenue | $8.96M | $11.57M | $10.64M | $11.12M | $11.91M | $9.86M | $8.46M | $10.23M |
| Gross profit | $26.29M | $26.09M | $24.07M | $29.47M | $26.30M | $27.34M | $30.45M | $30.55M |
| R&D expense | $3.10M | $2.70M | $2.38M | $3.75M | $3.47M | $2.93M | $2.28M | $3.18M |
| SG&A expense | $12.34M | $11.28M | $12.14M | $13.45M | $13.98M | $14.47M | $12.70M | $12.14M |
| Operating income | -$1.67M | -$2.04M | -$4.76M | $38,000 | -$4.09M | -$1.64M | $3.15M | $4.17M |
| Net income | -$5.01M | -$5.49M | -$8.11M | -$2.95M | -$17.50M | -$2.38M | $2.63M | $3.66M |
| EBITDA | -$1.28M | -$1.59M | -$4.24M | $575,000 | -$3.48M | -$1.03M | $3.71M | $4.75M |
| EPS (basic) | -0.03 | -0.03 | -0.04 | — | -0.10 | -0.02 | 0.02 | — |
| EPS (diluted) | -0.03 | -0.03 | -0.04 | — | -0.10 | -0.02 | 0.01 | — |
| Weighted avg. shares (diluted) | 190.92M | 190.34M | 189.65M | — | 170.35M | 154.02M | 196.92M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $11.60M | $20.72M | $26.12M | $28.65M | $43.07M | $16.52M | $19.27M | $25.80M |
| Short-term investments | $11.85M | $21.94M | $18.67M | $17.98M | $12.42M | $24.12M | $31.41M | $33.48M |
| Receivables | $86.73M | $89.57M | $83.69M | $89.59M | $81.05M | $79.93M | $78.74M | $78.88M |
| Inventory | $91.30M | $90.58M | $92.54M | $92.75M | $70.03M | $72.97M | $56.93M | $53.16M |
| Current assets | $209.11M | $229.84M | $228.98M | $238.07M | $229.40M | $210.92M | $212.84M | $209.01M |
| PP&E, net | $11.08M | $11.81M | $12.03M | $12.40M | $12.96M | $13.68M | $14.54M | $14.86M |
| Total assets | $230.45M | $252.26M | $246.22M | $255.88M | $248.95M | $232.09M | $235.75M | $233.15M |
| Current liabilities | $89.85M | $92.14M | $90.52M | $96.10M | $89.71M | $258.60M | $88.56M | $91.46M |
| Total liabilities | $225.53M | $245.35M | $237.08M | $241.54M | $234.06M | $259.35M | $264.20M | $266.80M |
| Shareholders' equity | $4.92M | $6.91M | $9.14M | $14.33M | $14.88M | -$27.26M | -$28.45M | -$33.65M |
| Shares outstanding | — | — | — | 188.31M | — | — | — | 152.13M |
| Cash flow statement | ||||||||
| Operating cash flow | -$794,000 | -$2.21M | -$1.54M | -$9.18M | $1.33M | -$10.87M | -$8.87M | -$11.78M |
| Capital expenditure | $102,000 | $138,000 | $391,000 | $0 | $0 | $208,000 | $109,000 | $638,000 |
| Free cash flow | -$896,000 | -$2.35M | -$1.93M | -$9.18M | $1.33M | -$11.08M | -$8.98M | -$12.42M |
| Investing cash flow | $10.09M | -$3.27M | -$939,000 | -$5.46M | $11.86M | $7.33M | $2.27M | $11.42M |
| Financing cash flow | -$18.43M | $82,000 | -$51,000 | $219,000 | $13.36M | $781,000 | $64,000 | $423,000 |
| Depreciation & amortization | $391,000 | $452,000 | $529,000 | $537,000 | $615,000 | $611,000 | $551,000 | $581,000 |
| Stock-based compensation | $3.08M | $3.18M | $2.98M | $2.18M | $2.85M | $2.80M | $2.51M | $2.29M |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.